ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, et al. Nature Medicine 2024
Read More
Nakamura, et al. Nature Medicine 2024
Read More
Read More
Honoré N, et al. ESMO 2025
Read More
Zhang Y, et al. Biomedicines. 2025
Read More
Abdelrahim M, et al. JCO Preci Oncol. 2025
Read More
Kim J, et al. Cancers 2025
Read More
Zaanan et al. Nat Commun, 2025
Read More
Read More
Read More
Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon
Watch Video
Powles et al, ASCO 2025
Read More
Ansstas et al, ASCO 2025
Read More
Mukhtar et al, ASCO 2025
Read More
Razavi et al, ASCO 2025
Read More
Pusztai et al, ASCO 2025
Read More
Read More
Read More
Read More
Read More
Watch Video
Loading More...